Trace Neuroscience Nets $101M in Series A Funding for ALS, Dementia Therapy Development

Senior Housing News November 19, 2024
Austin Montgomery

Trace Neuroscience Nets $101M in Series A Funding for ALS, Dementia Therapy Development

Biopharmaceutical company Trace Neuroscience announced it has raised $101 million in a Series A financing effort to develop new genomic therapies to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia and Alzheimer’s disease.

The funding effort was led by Third Rock Ventures with Atlas Venture, GV and RA Capital Management also participating in the fund.

The specific drugs to be developed by Trace aim to restore key brain proteins that can “re-establish” healthy communication between muscle and nerve cells that are affected by neurodegenerative diseases like Alzheimer’s disease and other forms of frontotemporal dementia.

The company’s lead therapeutic effort is aimed at improving the muscle...

Today's Sponsors

Today's Sponsor